Plecanatide vs hGHRH(1-40)OH
Head-to-head comparison of Plecanatide (Plecanatide) and hGHRH(1-40)OH (Human growth hormone-releasing factor (1-40) hydroxyl) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Plecanatide | hGHRH(1-40)OH |
|---|---|---|
| Category | Gastrointestinal | Growth Hormone |
| Full Name | Plecanatide | Human growth hormone-releasing factor (1-40) hydroxyl |
| Molecular Weight | Approx. 1620 Da | N/A |
| Half-Life | Local intestinal action; systemic half-life not clinically meaningful | 5-20 minutes |
| Amino Acids | 16 | 40 |
| Typical Dose | 3 mg once daily | 1-2 mcg/kg |
| Route | Oral | Subcutaneous/IV |
| Purity | ≥98% | ≥98% |
| Studies Count | 350 | 85 |
| Research Status | Clinical | Clinical Research |
Plecanatide Benefits
- ✓improves-stool-frequency
- ✓supports-fluid-secretion
- ✓may-reduce-constipation
- ✓local-gut-action
hGHRH(1-40)OH Benefits
- ✓GH secretion research
- ✓fragment-activity comparison
- ✓receptor binding studies
- ✓axis physiology modeling
Plecanatide Dosing
3 mg PO daily|take with or without food|avoid when dehydrated
hGHRH(1-40)OH Dosing
1-2 mcg/kg SC or IV in acute research settings|single-bolus GH stimulation protocols|repeated low-dose administration in comparative studies
Plecanatide Side Effects
- ⚠diarrhea
- ⚠abdominal-discomfort
- ⚠nausea
hGHRH(1-40)OH Side Effects
- ⚠flushing
- ⚠headache
- ⚠lightheadedness
Research Overview
Plecanatide
Clinical trials show plecanatide improves constipation outcomes with a generally favorable tolerability profile. Like linaclotide, it acts locally in the intestinal lumen via GC-C signaling rather than systemic hormone effects.
hGHRH(1-40)OH
Human GHRF(1-40)OH has been studied to understand how truncation of the native hormone changes biological potency and half-life. It is a common research tool for mapping minimal active sequences within the GHRH family.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.